Ipamorelin and Sermorelin are two peptides frequently studied in the context of growth hormone (GH) axis research. Both influence GH release but do so through distinct receptor targets and signalling mechanisms. Researchers investigating GH axis biology, somatotropic function, and related endocrine pathways often encounter both compounds — understanding their mechanistic differences is fundamental to appropriate experimental design.
Overview of Ipamorelin
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) classified as a growth hormone secretagogue (GHS). It functions as a selective agonist at the ghrelin receptor (GHS-R1a), mimicking the action of ghrelin — the endogenous GH-releasing acylated peptide produced primarily by the stomach.
In preclinical research, Ipamorelin has been investigated for its ability to stimulate pulsatile GH release from the anterior pituitary. A key feature noted in research literature is its selectivity: studies have suggested that Ipamorelin produces minimal stimulation of cortisol, prolactin, or ACTH compared to other GH secretagogues, making it of particular interest in research contexts where researchers wish to isolate GH axis effects without concurrent corticotropic or lactotropic perturbation.
Animal model studies have examined Ipamorelin in contexts including body composition research, bone density investigations, and GH-deficiency models. Its pentapeptide structure and receptor selectivity profile have made it a useful tool in pharmacological characterisation of the ghrelin receptor pathway.
Ipamorelin is a research compound available for laboratory investigation. It is not approved as a therapeutic agent in Canada.
Overview of Sermorelin
Sermorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), corresponding to the first 29 amino acids of endogenous GHRH (GHRH 1-29 NH2). Unlike Ipamorelin, which acts at the ghrelin receptor, Sermorelin acts directly at the GHRH receptor (GHRHR) on somatotroph cells of the anterior pituitary.
Because Sermorelin mimics the endogenous GHRH signal, its mechanism is considered more physiologically proximate to the natural hypothalamic-pituitary GH axis. Preclinical research has investigated Sermorelin’s effects on pulsatile GH secretion, IGF-1 levels, and downstream somatotropic signalling in animal models. It has also been studied in the context of GH deficiency models and age-related somatotropic decline research.
A prescription form of Sermorelin (Geref) previously held regulatory approval in the United States for diagnostic and therapeutic applications in paediatric GH deficiency, though this approval has been withdrawn. This history gives Sermorelin a relatively broader clinical research literature compared to many research peptides.
Sermorelin is available as a research-grade compound for laboratory use. It is not approved by Health Canada for therapeutic use.
Mechanism Comparison
| Feature | Ipamorelin | Sermorelin |
|---|---|---|
| Type | Synthetic pentapeptide GHS | Synthetic GHRH analogue (29 aa) |
| Receptor Target | GHS-R1a (ghrelin receptor) | GHRHR (GHRH receptor) |
| Mechanism | Ghrelin receptor agonism → pituitary GH pulse | GHRH receptor agonism → physiological GH release |
| Selectivity | High selectivity for GH release; minimal cortisol/prolactin effect reported | Acts via GHRH pathway; full somatotropic axis engagement |
| Research Context | Ghrelin pathway pharmacology, selective GH secretagogue studies | GHRH pathway studies, GH deficiency models, somatotropic aging |
| Clinical History | No approved clinical form | Prior FDA approval (Geref); now withdrawn |
Key Differences in Research Context
The fundamental mechanistic difference between Ipamorelin and Sermorelin is the receptor pathway through which each engages the GH axis. Ipamorelin acts through the ghrelin receptor — a G-protein coupled receptor (GPCR) that is part of a broader appetite and metabolic signalling network. Sermorelin acts through the GHRH receptor, which is the direct physiological target of hypothalamic GHRH.
This distinction is meaningful for research design. Researchers studying the ghrelin receptor pathway specifically, or interested in the pharmacological characterisation of GHS-R1a agonists, will find Ipamorelin more appropriate. Researchers studying GHRH pathway dynamics, pituitary somatotroph function, or physiological GH pulsatility patterns are more naturally served by Sermorelin-based experimental models.
The selectivity profile attributed to Ipamorelin in preclinical literature — particularly its reported low effect on cortisol and prolactin — is a feature of its receptor specificity rather than a universal property of GH secretagogues. This selectivity can be an advantage in research designs where isolating GH axis effects from corticotropic noise is a priority.
Sermorelin’s longer clinical research history, including prior regulatory approval status, provides a somewhat richer translational research context compared to Ipamorelin, which remains primarily a preclinical research tool.
Which to Choose for Research?
The choice between Ipamorelin and Sermorelin depends on the specific receptor pathway and GH axis component under investigation.
Research focused on the ghrelin receptor pathway, GHS-R1a pharmacology, or selective GH secretagogue activity is better aligned with Ipamorelin. Research focused on GHRH receptor signalling, physiological GH pulsatility, or the hypothalamic-pituitary GH axis in a more naturalistic mechanistic context is better aligned with Sermorelin.
Some GH axis research programs may incorporate both peptides in separate experimental arms to compare ghrelin-pathway and GHRH-pathway stimulation of GH secretion. All research should be conducted under appropriate institutional ethics review and regulatory compliance frameworks.
Neither compound is approved for human therapeutic use in Canada. This content does not provide dosing, administration, or human use guidance of any kind.
Related Research
For foundational context on research peptides, visit our Research Hub, What Are Peptides, and our guide to Research Peptides Explained. For purity and quality standards, see Quality and Purity.
Compound guides: What Is Ipamorelin?
Compliance Disclaimer: This content is intended for educational and informational purposes in the context of scientific research only. Ipamorelin and Sermorelin are research compounds not approved by Health Canada as therapeutic agents for human use. This content does not constitute medical advice and is not intended to diagnose, treat, cure, or prevent any disease or health condition. No dosing, cycling, administration, or human use guidance is provided or implied. All research must be conducted under appropriate institutional oversight and in compliance with applicable Canadian regulations. Consult a qualified healthcare professional for any health-related concerns.
Related Products
📖 Compound profile: What Is Sermorelin? →